{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(17)"],"submitter":["Styczen H"],"pubmed_abstract":["<h4>Objective</h4>In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.<h4>Patients and methods</h4>Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.<h4>Results</h4>Positivity of HER-2 status (IHC score 2+/ISH+ and"],"journal":["Oncotarget"],"pagination":["15065-76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4558136"],"repository":["biostudies-literature"],"pubmed_title":["HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer."],"pmcid":["PMC4558136"],"pubmed_authors":["Styczen H","Sprenger T","Conradi LC","Ghadimi BM","Beissbarth T","Ruschoff J","Nagelmeier I","Stanek K","Boczek U","Nietert M","Middel P","Liersch T","Homayounfar K","Wolff HA","Kitz J"],"additional_accession":[]},"is_claimable":false,"name":"HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.","description":"<h4>Objective</h4>In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.<h4>Patients and methods</h4>Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.<h4>Results</h4>Positivity of HER-2 status (IHC score 2+/ISH+ and","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jun","modification":"2026-05-30T13:37:52.297Z","creation":"2019-03-27T01:57:44Z"},"accession":"S-EPMC4558136","cross_references":{"pubmed":["25915155"],"doi":["10.18632/oncotarget.3527"]}}